Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen
Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen
复制标题
DOI：
10.1016/j.vaccine.2012.02.072
复制
发表时间：
2012-04-19
期刊：
影响因子：
5.5
通讯作者：
Howard, John A.
中科院分区：
文献类型：
--
作者：
Hayden, Celine A.;Streatfield, Stephen J.;Howard, John A.
尽管有安全有效的疫苗可用，但乙肝仍然是一个主要的全球健康问题。部分人群无法获得非肠道疫苗或对该疫苗反应不佳，从而延长了感染-传播循环。一种低成本的口服疫苗有可能缓解其中的许多问题。在这里，我们描述了一种生物包裹的乙肝表面抗原在玉米中的表达及其免疫原性，首次展示了一种商业上可行的针对重大疾病的口服亚单位疫苗生产系统。这项工作克服了以前植物生产疫苗的障碍，表达了更高水平的乙肝表面抗原，并在后处理过程中保留了抗原的免疫原性：这些因素促进了小鼠在不需要佐剂的情况下产生强大的免疫反应。这种方法为低成本、稳定的口服疫苗的交付提供了一种实用的解决方案。(C)2012爱思唯尔有限公司。保留所有权利。
Hepatitis B remains a major global health problem despite the availability of a safe and effective vaccine. Segments of the population lack access to or respond poorly to the parenteral vaccine, perpetuating the infection-transmission cycle. A low cost, orally delivered vaccine has the potential to alleviate many of these problems. Here we describe the expression of a bioencapsulated hepatitis B surface antigen (HBsAg) in maize and its immunogenicity, demonstrating for the first time a commercially feasible oral subunit vaccine production system for a major disease. This work surmounts previous barriers to plant-produced vaccines by expressing HBsAg at much higher levels and retaining antigen immunogenicity post-processing: factors which facilitated a robust immune response in mice without the need for an adjuvant. This method provides a practical solution to the delivery of a low-cost, stable oral vaccine. (C) 2012 Elsevier Ltd. All rights reserved.